

# Case Study: Plan Sponsors Navigate Usage and Coverage of Ozempic and Other GLP-1 Drugs

MultiPlan's BenInsights™ Platform helps manage healthcare benefits through data-backed trend analysis

## The Situation

The use of Ozempic and other GLP-1 diabetic drugs for weight loss purposes has gained attention in the context of employer-sponsored health plan coverage. Employers are struggling with making appropriate benefits design decisions around the GLP-1 medications used for this purpose.

## The Problem

The average cost for Ozempic and other GLP-1 drugs before insurance ranges from around \$900 to over \$1,000 per month. With employer-sponsored health plans, employers are responsible for most of the costs. According to data accumulated through MultiPlan's BenInsights™ Platform, we saw 80% year-over-year spend increase on the GLP-1 drugs in 2023, averaging \$162 per member per year. Employers hoped the spend on GLP-1 drugs could help their members better manage type-2 diabetes and other comorbidities and deter them from becoming high-cost claimants, but the challenge was first identifying who **should not** take GLP-1 drugs.

## The Actions


Using the BenInsights platform, the employer easily identified the uptick spend on GLP-1 drugs and quantified the financial impact of inappropriate GLP-1 drug use.

- **Identified inappropriate GLP-1 drug usage**

By aggregating medical and pharmacy data on the BenInsights platform, our Smart Card quickly identified members using GLP-1 drugs who did not have a medical diagnosis of diabetes or obesity in the past 24 months.

- **Recommended prior authorization review by PBM**

The employer sent a list of members who were inappropriately using GLP-1 drugs to their PBM, which conducted a second prior authorization review on each individual.



This analysis helped the employer avoid future spend on inappropriate use of GLP-1 drugs. Further, BenInsights continues to monitor overall healthcare spend and health outcomes of members using GLP-1 drugs.